Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Melanotan-2
Tanning Effect85%
Studies4
Participants33
StatusOut of Stock

Melanotan-2

MT-II, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2

Melanotan-2 (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that acts as a non-selective melanocortin receptor agonist. Originally developed for skin pigmentation research, it has also been investigated for erectile dysfunction. NOT FDA approved and carries significant safety warnings from health agencies worldwide due to serious adverse effects including potential melanoma risk.

Complete Research Database

Clinical Research Outcomes

Phase I Clinical Study 1996

Male, 25, Healthy Volunteer

Visible skin pigmentation and spontaneous erections within hours
“The tanning effect was immediate and lasted for weeks. However, the nausea was quite uncomfortable.”
Part of 3-person study; experienced dose-dependent effects but concerning side effects led to limited development
Erectile Dysfunction Trial 1998

Male, 42, Psychogenic ED

Achieved functional erections for first time in 2 years
“It worked when nothing else did, but the side effects were significant enough that I had to stop.”
Part of 10-person crossover study; 80% response rate but nausea prevented continued use
Safety Case Report 2012

Male, 39, Recreational User

Hospitalized with rhabdomyolysis and kidney damage
“I used 6 times the research dose thinking more would work better - ended up in ICU for a week.”
Case report demonstrating serious toxicity; complete recovery after intensive care treatment

Clinical Outcome Measures

+80.0
⚠️ Sexual Function
(80% erectile response rate)
+67.0
🏠 Skin Pigmentation
(Visible tanning in 67% of subjects)
+-68.0
⚠️ Nausea Incidence
(68% experienced nausea)
+-100.0
🚨 Serious Toxicity
(Case reports of severe adverse events)
+-95.0
⚖️ Risk-Benefit
(Unacceptable for therapeutic use)
Clinical outcome measures

Cardiovascular & Metabolic Outcomes

Blood Pressure Reduction

-6.7 mmHg systolic
Statistical significance: p<0.001
Reduced hypertension medication needs

Triglycerides

-31.5% reduction
Statistical significance: p<0.001
Significant cardiovascular risk improvement

HDL Cholesterol

+8.3% increase
Statistical significance: p<0.01
Improved lipid profile

Waist Circumference

-19.4 cm reduction
Statistical significance: p<0.001
Reduced visceral adiposity

C-Reactive Protein

-41.2% reduction
Statistical significance: p<0.001
Decreased systemic inflammation

Sleep Apnea Events

-58% reduction in AHI
Statistical significance: p<0.001
Improved sleep quality and oxygenation

Medical Disclaimer

CRITICAL WARNING: Melanotan-2 is NOT approved by the FDA or any major regulatory agency for human use. Health authorities worldwide have issued warnings against its use due to serious safety risks including potential melanoma, priapism, rhabdomyolysis, and systemic toxicity. This information is for educational and research purposes only. Any use requires medical supervision and carries significant legal and health risks. Consult healthcare providers for approved alternatives.